Reviva Pharmaceuticals Shares Exciting Update on Global Enrollment for Pivotal Phase 3 RECOVER Study: A Promising Step Towards Evaluating Brilaroxazine for Schizophrenia Treatment
Reviva Pharmaceuticals Announces Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia Enrollment ongoing at multiple sites in the US and Europe; site initiation in Asia expected in November 2022 Enrollment on pace, with over 30% enrolled in the United States Topline data for RECOVER evaluating brilaroxazine for schizophrenia expected in…